BRPI0506705A - composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos - Google Patents

composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos

Info

Publication number
BRPI0506705A
BRPI0506705A BRPI0506705-7A BRPI0506705A BRPI0506705A BR PI0506705 A BRPI0506705 A BR PI0506705A BR PI0506705 A BRPI0506705 A BR PI0506705A BR PI0506705 A BRPI0506705 A BR PI0506705A
Authority
BR
Brazil
Prior art keywords
formula
compounds
pharmaceutical compositions
compound
suffering
Prior art date
Application number
BRPI0506705-7A
Other languages
English (en)
Inventor
Andrew Thurkauf
Dawei Chen
Avinash Phadke
Shouming Li
Milind Deshpande
Original Assignee
Achillion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achillion Pharmaceuticals Inc filed Critical Achillion Pharmaceuticals Inc
Publication of BRPI0506705A publication Critical patent/BRPI0506705A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSTOS DE TIOURéIAS AZABENZOFURAN-SUBSTITUìDAS, COMPOSIçõES FARMACêUTICAS E SEUS USOS A presente invenção fornece compostos de Formula: (1), em que as variáveis AR, A~ 1~, A~ 2~, A~ 3~, A~ 4~, R~ 5~, R~ 6~, R~ 7~, V, W, X e Y são aqui definidos. certos compostos de fórmula (1) aqui descritos possuem atividade antiviral potente. A invenção também fornece compostos de fórmula (1) que são inibidores potentes e/ou seletivos da replicacão do vírus da Hepatite c. A invenção também fornece composições farmacêuticas contendo um ou mais compostos de fórmula (1), ou um sal, solvato ou pró-droga acilada destes compostos, e um ou mais veículos, excipientes ou diluentes farmaceuticamente aceitáveis A invençao ainda compreende métodos de tratamento de pacientes que sofrem de de certas doenças infecciosas pela administração a estes pacientes de uma quantidade de um composto de fórmula (1) eficaz para reduzir sinais ou sintomas da doença. Estas doenças infecciosas incluem infecções virais, particularmente infecções pelo HCV. A invenção inclui particularmente métodos de tratamento de pacientes humanos que sofrem de uma doença infecciosa,mas também engloba métodos de tratamento de outros animais, incluindo animais de criação e animais domesticados companhia, que sofrem de uma doença infecciosa. os métodos de tratamento incluem a administração de um composto de fórmula (1) como um agente ativo único ou a administração de um composto de fórmula (1) em combinação com um ou mais outros agentes terapêuticos.
BRPI0506705-7A 2004-01-06 2005-01-05 composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos BRPI0506705A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53483904P 2004-01-06 2004-01-06
PCT/US2005/000339 WO2005067900A2 (en) 2004-01-06 2005-01-05 Azabenzofuran substituted thioureas as inhibitors of viral replication

Publications (1)

Publication Number Publication Date
BRPI0506705A true BRPI0506705A (pt) 2007-05-02

Family

ID=34794326

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506705-7A BRPI0506705A (pt) 2004-01-06 2005-01-05 composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos

Country Status (19)

Country Link
US (1) US7439374B2 (pt)
EP (1) EP1709047B1 (pt)
JP (1) JP2007517887A (pt)
KR (1) KR20060121289A (pt)
CN (1) CN1946720A (pt)
AP (1) AP2006003659A0 (pt)
AR (1) AR047367A1 (pt)
AT (1) ATE479684T1 (pt)
AU (1) AU2005204369B2 (pt)
BR (1) BRPI0506705A (pt)
CA (1) CA2552002A1 (pt)
DE (1) DE602005023266D1 (pt)
EA (1) EA200601281A1 (pt)
IL (1) IL176486A0 (pt)
NO (1) NO20062928L (pt)
NZ (1) NZ548375A (pt)
OA (1) OA13357A (pt)
TW (1) TW200528459A (pt)
WO (1) WO2005067900A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
TWI329102B (en) * 2006-08-15 2010-08-21 Nat Health Research Institutes Thiourea compounds and method for inhibiting hepatitis c virus infection
AU2007286754A1 (en) * 2006-08-25 2008-02-28 Viropharma Incorporated Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2008124300A1 (en) * 2007-04-10 2008-10-16 National Health Research Institutes Hepatitis c virus inhibitors
TW200848016A (en) * 2007-06-08 2008-12-16 Nat Health Research Institutes Thiourea compound and composition of treating hepatitis C virus infection
TWI361808B (en) * 2008-01-08 2012-04-11 Nat Health Research Institutes Imidazolidinone and imidazolidinethione derivatives
US8198284B2 (en) * 2008-04-30 2012-06-12 National Health Research Institutes Treatment of neurodegenerative disorders with thiourea compounds
US8198449B2 (en) * 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
MX2011006890A (es) 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
AP2012006535A0 (en) 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
HRP20180237T4 (hr) 2011-09-16 2020-12-11 Gilead Pharmasset Llc Metode za liječenje hcv-a
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN103467482B (zh) * 2012-04-10 2017-05-10 上海璎黎药业有限公司 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
KR102218333B1 (ko) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2241470A1 (de) * 1971-08-23 1973-03-22 Midizinska Akademia Arzneimittel mit antivirus-wirksamkeit
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
GB9504460D0 (en) * 1995-03-06 1995-04-26 Bayer Ag N-(3-Benzofuranyl)urea-derivatives
JP2000510833A (ja) * 1996-05-06 2000-08-22 イーライ・リリー・アンド・カンパニー 抗―ウイルス性化合物群
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US7265152B2 (en) * 2002-11-01 2007-09-04 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases
CN1738797A (zh) * 2002-11-19 2006-02-22 阿基里昂药品公司 取代的芳基硫脲和相关的化合物,病毒复制的抑制剂
BRPI0412502A (pt) * 2003-07-10 2006-09-19 Achillion Pharmaceuticals Inc derivados de ariltiouréia substituìda úteis como inibidores de replicação viral

Also Published As

Publication number Publication date
WO2005067900A2 (en) 2005-07-28
NO20062928L (no) 2006-08-03
OA13357A (en) 2007-04-13
EP1709047A2 (en) 2006-10-11
AU2005204369A1 (en) 2005-07-28
WO2005067900A3 (en) 2005-09-29
AP2006003659A0 (en) 2006-06-30
TW200528459A (en) 2005-09-01
JP2007517887A (ja) 2007-07-05
CN1946720A (zh) 2007-04-11
US20050228013A1 (en) 2005-10-13
IL176486A0 (en) 2006-10-05
NZ548375A (en) 2010-07-30
EA200601281A1 (ru) 2006-12-29
CA2552002A1 (en) 2005-07-28
ATE479684T1 (de) 2010-09-15
DE602005023266D1 (de) 2010-10-14
EP1709047B1 (en) 2010-09-01
KR20060121289A (ko) 2006-11-28
AR047367A1 (es) 2006-01-18
AU2005204369B2 (en) 2010-06-10
US7439374B2 (en) 2008-10-21

Similar Documents

Publication Publication Date Title
BR0316397A (pt) Tiouréias aril substituìdas e compostos relacionados como inibidores de replicação viral
UA92746C2 (en) Thiazole compounds and methods of use
TW200600492A (en) Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
WO2005067900A3 (en) Azabenzofuran substituted thioureas as inhibitors of viral replication
Geier et al. A review of Thimerosal (Merthiolate) and its ethylmercury breakdown product: specific historical considerations regarding safety and effectiveness
ES2988617T3 (es) Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales
Imran et al. Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
BR0309670A (pt) Compostos derivados dicetohidrazina e drogas contendo os compostos como o ingrediente ativo
ES2187575T3 (es) Hexapeptidos ciclicos dotados de actividad antibiotica.
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
KR20120044930A (ko) 고병원성 감염성 질환의 예방 및 치료제
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
BR112022019198A2 (pt) Composição farmacêutica para a prevenção ou tratamento de infecções por vírus de ácido ribonucleico epidêmico, e, uso de uma quantidade terapeuticamente eficaz de pironaridina ou um sal farmaceuticamente aceitável da mesma e artemisinina ou um derivado da mesma
WO2005095345A3 (en) Heteroaryl guanidines as inhibitors of viral replication
BRPI0407140A (pt) Droga terapêutica para vìrus
RU2738719C1 (ru) Средство для лечения коронавирусных, ретровирусных инфекций и гепатита с
JP2023520703A5 (pt)
EA202100186A2 (ru) Вакцина и способ защиты от коронавирусной инфекции
ES2359346T3 (es) Uso de análogos de tetraciclina no antibacteriana y sus formaulaciones para el tratamiento de exotoxinas bacterianas.
ES2207166T3 (es) Composicion fungicida que comprende una benzoilfenilurea.
KR20230015320A (ko) 감염성 질환의 치료에서의 부실라민의 용도
WO2021195185A1 (en) Method of treating coronavirus infection by administration of ethyl mercury or thiol derivative thereof
KR20060054190A (ko) 코로나 바이러스를 불활성화시키는 제제
RU2420309C2 (ru) Препарат против бешенства

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.